Figure 4. The antidepressant effects of GLYX-13 are due to NMDAR-triggered synaptic plasticity.

GLYX-13 (3 mg/kg IV, 24 h post-dosing): (A) enhances the magnitude of hippocampus ex vivo long-term potentiation, (B) antidepressant-like effect is blocked by the AMPA/kainate antagonist NBQX, (C) increases hippocampus NR2B current, and (D) increases cell surface expression of NR2B and GluR1 protein levels in the medial prefrontal cortex and hippocampus.

Data are expressed as Mean ± SEM. *p < 0.05 Fisher’s PLSD post hoc test vs. vehicle.

Data adapted from [34] with permission of Nature Publishing Group.